Trefoil Therapeutics

FOUNDED: 2014

CEO: David Eveleth, Ph.D.

HEADQUARTERS: San Diego, Sorrento Valley

BUSINESS: Clinical-stage biotechnology company leveraging its engineered FGF-1 protein technology platform to develop pharmacologic treatments for serious corneal endothelial diseases and epithelial disorders.

EMPLOYEES: 10

WEBSITE: www.trefoiltherapeutics.com

NOTABLE: Trefoil's FGF1 compound could replace many cornea transplant surgeries.